Oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalation

Trial Profile

Oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Tegafur/uracil (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 14 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Aug 2013 as reported by University Hospital Medical Information Network - Japan.
    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top